Riskpilot← Back to searchSign inGet full accessSENSE BIOPHARMA AS
ASActiveOrg 987700378Karl Johans Gate 16, 0154 OsloForskning og utviklingsarbeid innen bioteknologi · NACE 72110Est. 20050 employees
Revenue 2020
NOK 0
EBITDA margin
—
-384% vs 2019
Equity ratio
-619.1%
Financial strength
Net profit 2020
NOK -10,4M
-390% vs 2019
| Revenue | NOK 0 | — |
| EBITDA | NOK -10,3M | -384% |
| Net profit | NOK -10,4M | -390% |
| Total assets | NOK 440K | +1071% |
| Equity | NOK -2,7M | -13% |
| Employees | 0 | — |
Legal name
SENSE BIOPHARMA AS
Org number
987700378
Legal form
Aksjeselskap
NACE code
72110 · Forskning og utviklingsarbeid innen bioteknologi
Founded
17. januar 2005
Share capital
NOK 1 231 200
Employees
0
VAT registered
No
Audit selected
No
Last report
2020-12-31
Financial year
January – December
Signatory rights
Styrets leder alene.
Company purpose
Utvikle kommersielle rna terapier og utvikle en generisk rna kommersialiserings- modell fra forskning fram til legemiddelutvikling. Formålet kan fremmes ved deltagelse i eller i samarbeid med andre foretak i inn-og utland.
Address
Karl Johans Gate 16, 0154 Oslo
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2016 | 2017 | 2018 | 2019 | 2020 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | −0 | −0 | −0 | −182 | −0 |
| EBITDA | −32 | 0 | −300 | −2 129 | −10 298 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −6 |
| EBIT | −32 | 0 | −300 | −2 129 | −10 304 |
| Net financials | 3 | −0 | 0 | −2 | −133 |
| Profit before tax | −30 | −0 | −300 | −2 131 | −10 437 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −30 | −0 | −300 | −2 131 | −10 437 |
| Item | 2016 | 2017 | 2018 | 2019 | 2020 |
|---|---|---|---|---|---|
| Total assets | 16 | 16 | 717 | 38 | 440 |
| Equity | 17 | 17 | −283 | −2 414 | −2 727 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | −0 | 0 | 1 000 | 2 452 | 3 167 |
| Total debt | −0 | 0 | 1 000 | 2 452 | 3 167 |
EBITDA margin
-1029847400.0%
This company
15.8%
Market median
-6518021619% vs market
20162020
Equity ratio
-619.1%
This company
38.2%
Market median
-1721% vs market
20162020
Return on equity
-1043716100.0%
This company
18.4%
Market median
-5672370209% vs market
20162020
Net profit margin
-1043716100.0%
This company
8.1%
Market median
-12885384051% vs market
20162020
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20162020
Debt / equity
1.16×
This company
0.62×
Market median
-87% vs market
20162020
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2016-01-01 – 2016-12-31
| Name | Role | Member since |
|---|---|---|
| Former (1) | ||
MD Chief Executive Officer | Chief Executive Officer | 2020 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
| Board of Directors | 2021 | |
| Board of Directors | 2021 | |
| Chairman | 2021 | |
| Board of Directors | 2021 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of SENSE BIOPHARMA AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Mariann Dønnum | Chief Executive Officer | 0 companies |
| Stephen Lewis Minger | Board of Directors | 0 companies |
| Camila Vicencio Esguerra | Board of Directors | 0 companies |
| Dag Øivind Dvergsten | Chairman | 0 companies |
| Jon Morten Melhus | Board of Directors | 0 companies |